Ventyx Biosciences (VTYX) News Today $1.87 -0.10 (-5.08%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Ventyx Biosciences' (VTYX) "Neutral" Rating Reiterated at HC WainwrightNovember 14 at 1:45 AM | americanbankingnews.comVentyx Biosciences to Participate in Three Upcoming Investor ConferencesNovember 12, 2024 | globenewswire.comVentyx Biosciences: Strong Financial Position and Promising Pipeline Drive Buy RatingNovember 12, 2024 | markets.businessinsider.comVentyx Biosciences Reports Q3 Financial Results and Pipeline ProgressNovember 11, 2024 | tipranks.comVentyx Biosciences (NASDAQ:VTYX) Earns "Neutral" Rating from HC WainwrightHC Wainwright restated a "neutral" rating and set a $6.00 target price on shares of Ventyx Biosciences in a research report on Monday.November 11, 2024 | marketbeat.comOppenheimer Reaffirms "Outperform" Rating for Ventyx Biosciences (NASDAQ:VTYX)November 10, 2024 | americanbankingnews.comVentyx Biosciences (VTYX) Receives a Buy from LifeSci CapitalNovember 9, 2024 | markets.businessinsider.comVentyx Biosciences (VTYX) Gets a Buy from OppenheimerNovember 9, 2024 | markets.businessinsider.comVentyx Biosciences' (VTYX) Outperform Rating Reaffirmed at OppenheimerOppenheimer reissued an "outperform" rating and issued a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a research report on Friday.November 8, 2024 | marketbeat.comVentyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate ProgressNovember 8, 2024 | markets.businessinsider.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight analysts that are covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company.October 28, 2024 | marketbeat.comFY2024 EPS Estimates for Ventyx Biosciences, Inc. Cut by HC Wainwright (NASDAQ:VTYX)Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) - Research analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for shares of Ventyx Biosciences in a research report issued on Tuesday, October 15th. HC Wainwright analyst E. Bodnar now forecasts that the companyOctober 17, 2024 | marketbeat.comVentyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024October 16, 2024 | finance.yahoo.comVentyx Biosciences (NASDAQ:VTYX) Given "Neutral" Rating at HC WainwrightHC Wainwright reaffirmed a "neutral" rating and set a $6.00 price target on shares of Ventyx Biosciences in a research note on Tuesday.October 15, 2024 | marketbeat.comVentyx Biosciences Inc VTYXOctober 10, 2024 | morningstar.comDeerfield Management Company L.P. Series C Buys 2,287,570 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)Deerfield Management Company L.P. Series C lifted its position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 64.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,829,570 shares of theSeptember 26, 2024 | marketbeat.comEquities Analysts Set Expectations for Ventyx Biosciences, Inc.'s FY2024 Earnings (NASDAQ:VTYX)Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) - HC Wainwright upped their FY2024 EPS estimates for shares of Ventyx Biosciences in a research note issued on Monday, September 23rd. HC Wainwright analyst E. Bodnar now expects that the company will earn ($2.13) per share for the year, up froSeptember 26, 2024 | marketbeat.comOppenheimer Sticks to Its Buy Rating for Ventyx Biosciences (VTYX)September 24, 2024 | markets.businessinsider.comVentyx Biosciences (NASDAQ:VTYX) Stock Quotes, Forecast and News SummarySeptember 24, 2024 | benzinga.comVentyx Biosciences: Cautious Optimism Amidst Sanofi’s Strategic Investment and Upcoming Clinical TrialsSeptember 24, 2024 | markets.businessinsider.comVentyx Biosciences Shares Rise Premarket on Sanofi InvestmentSeptember 23, 2024 | marketwatch.comVentyx Biosciences Announces $27 Million Strategic Investment from SanofiSeptember 23, 2024 | finance.yahoo.comAcadian Asset Management LLC Invests $608,000 in Ventyx Biosciences, Inc. (NASDAQ:VTYX)Acadian Asset Management LLC purchased a new stake in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 263,565 shares of the company's stock, valueSeptember 18, 2024 | marketbeat.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Given Consensus Rating of "Moderate Buy" by AnalystsVentyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight brokerages that are presently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and four have issued a buSeptember 8, 2024 | marketbeat.comVentyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s DiseaseSeptember 7, 2024 | markets.businessinsider.comVentyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's DiseaseSeptember 6, 2024 | globenewswire.comVentyx Biosciences Finance Chief Steps DownAugust 30, 2024 | marketwatch.comVentyx Biosciences Chief Financial Officer Martin Auster Steps DownAugust 30, 2024 | markets.businessinsider.comVentyx Biosciences Announces Departure of Chief Financial OfficerAugust 30, 2024 | globenewswire.comVentyx Biosciences to Participate in Two Upcoming Investor ConferencesAugust 28, 2024 | globenewswire.comVentyx Biosciences (NASDAQ:VTYX) PT Lowered to $11.00Wells Fargo & Company reduced their price objective on Ventyx Biosciences from $16.00 to $11.00 and set an "overweight" rating for the company in a research note on Monday.August 12, 2024 | marketbeat.comVentyx Biosciences (NASDAQ:VTYX) Announces Earnings Results, Beats Expectations By $0.12 EPSVentyx Biosciences (NASDAQ:VTYX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.12.August 10, 2024 | marketbeat.comVTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q2 2024August 9, 2024 | investorplace.comVentyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate ProgressAugust 8, 2024 | globenewswire.comVentyx Biosciences: Hold Rating Affirmed Amid Clinical and Strategic SetbacksJuly 30, 2024 | markets.businessinsider.comVentyx Proposed Crohn's Treatment Fails in Phase 2 StudyJuly 30, 2024 | marketwatch.comVentyx Biosciences Shares Tumble After VTX958 Study FailureJuly 29, 2024 | marketwatch.comVentyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn’s DiseaseJuly 29, 2024 | finance.yahoo.comLifeSci Capital Keeps Their Buy Rating on Ventyx Biosciences (VTYX)July 29, 2024 | markets.businessinsider.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Recommendation of "Moderate Buy" from BrokeragesVentyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine research firms that are covering the company, MarketBeat reports. Four analysts have rated the stock with a hold recommendation and five have given a buy recommendation toJuly 20, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (9EP.F)July 19, 2024 | finance.yahoo.comVENTYX STOCK ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for DetailsJune 25, 2024 | globenewswire.comVENTYX INVESTOR ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for DetailsJune 22, 2024 | globenewswire.comVENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading SchemeJune 20, 2024 | globenewswire.comVENTYX INSIDER TRADING ALERT: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding LossesJune 18, 2024 | globenewswire.comOpaleye Management Inc. Makes New $2.82 Million Investment in Ventyx Biosciences, Inc. (NASDAQ:VTYX)Opaleye Management Inc. bought a new position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 1,140,000 shares of the company's stock, valued at approximately $2,816,00June 15, 2024 | marketbeat.comVENTYX REMINDER: BFA Law is Investigating Ventyx (Nasdaq: VTYX) Directors for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact the FirmJune 13, 2024 | globenewswire.comVENTYX INVESTIGATION ANNOUNCEMENT: Ventyx (Nasdaq: VTYX) Stock Drops 20%, Investors are Urged to Contact BFA Law about the Investigation into the Company's BoardJune 11, 2024 | globenewswire.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Capital International InvestorsCapital International Investors cut its holdings in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 13.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,354,149 shares of the company's stock after seJune 8, 2024 | marketbeat.comVENTYX NEWS NOTICE: Ventyx (Nasdaq: VTYX) Shareholders are Urged to Contact BFA Law about the Investigation into the Company's Board of DirectorsJune 8, 2024 | globenewswire.com Get Ventyx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Back, but DC’s Coming for Your Money! (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back… Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov VTYX Media Mentions By Week VTYX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VTYX News Sentiment▼0.080.55▲Average Medical News Sentiment VTYX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VTYX Articles This Week▼74▲VTYX Articles Average Week Get Ventyx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Y-mAbs Therapeutics News Today Acelyrin News Today Larimar Therapeutics News Today Mereo BioPharma Group News Today VectivBio News Today Phathom Pharmaceuticals News Today Monte Rosa Therapeutics News Today ChromaDex News Today PureTech Health News Today Corvus Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VTYX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
